Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-naive prostate cancer in the GETUG-AFU 15 phase 3 trial

Nom du journal : Eur Urol

Année : 2018

Volume : 73

Page de départ : 696

Page de fin : 703

Auteurs: Boher JM, Zanetta S, Habibian M, Tubiana-Mathieu N, Deplanque G, Linassier C, Baciuchka M, Dauba J, Laguerre B, Mourey L, Berdah JF, Priou F, Ferrero JM, Pouessel D, Latorzeff I, Hasbini A, Bousquet G, Rolland F, Culine S, Gravis G, Théodore C, Oudard S, Eymard JC, Beuzeboc P, Soulié M, Fizazi K, Joly F, Delva R, Krakowski I, Ravaud A, Lavaud P, Foulon S, Platini C, Machiels JP, Kouri CE, Suc E, Tergemina-Clain G, Legoupil C,